Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –
Novan to Provide Corporate Update at its 2023 Annual Meeting of StockholdersDURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format.
Novan Focuses Strategic Direction and Announces Restructuring– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum –
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) –
Novan to Report First Quarter 2023 Financial Results on May 15, 2023DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDLive moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 –
Novan Announces Closing of $6.0 Million Registered Direct OfferingDURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.
Novan Announces $6.0 Million Registered Direct OfferingDURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.
Novan Moves Forward with Unified Corporate Branding– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization –
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines –
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in JapanDURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”) granting Sato the right to develop, manufacture and market RHOFADE® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan.
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET –
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year –
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference® being held October 20-23, 2022, in Las Vegas, NV.
